Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2007

BaroFold Contracts Avecia for Optimization and Manufacturing Scale-Up

  • Avecia Biologics will provide BaroFold with process development and cGMP manufacture of its lead compound, BaroFeron™, interferon beta-1b. Interferon betas are used in the treatment of multiple sclerosis and other autoimmune disorders.

    Avecia will carry out development work to optimize and scale up the drug manufacturing process for BaroFeron, using BaroFold’s PreEMT™ protein-processing technology. Avecia will integrate the operation of this platform alongside other stages of protein purification in both pilot and cGMP facilities.

    PreEMT involves the use of high hydrostatic pressure to potentially disaggregate and refold proteins. It is intended to enable improved, safer, protein therapeutics, potentially providing enhanced product life cycle.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »